Active Watch List: Onconova Therapeutics Inc (NASDAQ:ONTX), Sangamo Biosciences (NASDAQ:SGMO), bluebird bio Inc (NASDAQ:BLUE), Shire PLC (ADR) (NASDAQ:SHPG)

Onconova Therapeutics Inc (NASDAQ:ONTX), issued its quarterly earnings data on Tuesday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.09, Stock Ratings Network reports. Onconova Therapeutics Inc (NASDAQ:ONTX), weekly performance is -10.31%. On last trading day company shares ended up $4.87. Analysts mean target price for the company is $11.50. Onconova Therapeutics Inc (NASDAQ:ONTX), distance from 50-day simple moving average (SMA50) is -3.13%.

Sangamo Biosciences, Inc. (NASDAQ:SGMO), SVP Philip D. Gregory sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $15.66, for a total transaction of $234,900.00. Following the completion of the sale, the senior vice president now directly owns 109,347 shares in the company, valued at approximately $1,712,374. Sangamo Biosciences, Inc. (NASDAQ:SGMO), fell 9.02% in last trading session and ended the day on $13.52. SGMO, return on assets is -17.90%. Sangamo Biosciences, Inc. (NASDAQ:SGMO), quarterly performance is -15.55%.

bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $34.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase from it up to an additional 450,000 shares of common stock. bluebird bio Inc (NASDAQ:BLUE), shares moved down 8.71% in last trading session and was closed at $34.35, while trading in range of $33.80 – 36.89. bluebird bio Inc (NASDAQ:BLUE), year to date (YTD) performance is 63.73%.

Shire PLC (ADR) (NASDAQ:SHPG)‘s stock had its “outperform” rating reiterated by BNP Paribas in a research note issued on Thursday. They currently have a GBX 3,600 ($61.75) price objective on the stock. BNP Paribas’ price target indicates a potential downside of 22.33% from the company’s current price. Shire PLC (ADR) (NASDAQ:SHPG), ended the last trading day at $232.92.